Pulmonary arterial hypertension (PAH) refers to a set of heterogeneous vascular diseases defined by elevation of pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR), leading to right ventricular (RV) remodeling and often death. Early increases in pulmonary artery stiffness in PAH drive pathogenic alterations of pulmonary...
-
May 1, 2021 (v1)Journal articleUploaded on: December 4, 2022
-
June 15, 2021 (v1)Journal article
BACKGROUND: Pulmonary hypertension (PH) is a deadly disease characterized by vascular stiffness and altered cellular metabolism. Current treatments focus on vasodilation and not other root causes of pathogenesis. Previously, it was demonstrated that glutamine metabolism, as catalyzed by GLS1 (glutaminase 1) activity, is mechanoactivated by...
Uploaded on: December 4, 2022 -
August 14, 2020 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
September 1, 2016 (v1)Journal articleVascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension
International audience
Uploaded on: December 4, 2022